Helen Louise Collins
CHIEF MEDICAL OFFICER; Director · 5 filings · Latest: Jun 4, 2026
Enliven Therapeutics, Inc.
Kura Oncology, Inc.
| Ticker | Owner | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
ELVN | Helen Louise Collins | CHIEF MEDICAL OFFICER | May 18, 2026 | Sale | $39.79 | 5,000 | $199.0K | 25,000 | |
ELVN | Helen Louise Collins | CHIEF MEDICAL OFFICER | May 18, 2026 | Option Exercise | $2.48 | 5,000 | $12.4K | 30,000 | |
ELVN | Helen Louise Collins | CHIEF MEDICAL OFFICER | Apr 17, 2026 | Sale | $47.67 | 5,000 | $238.4K | 25,000 | |
ELVN | Helen Louise Collins | CHIEF MEDICAL OFFICER | Apr 17, 2026 | Option Exercise | $2.48 | 5,000 | $12.4K | 30,000 | |
ELVN | Helen Louise Collins | CHIEF MEDICAL OFFICER | Mar 25, 2026 | Sale | $35.10 | 40,000 | $1.4M | 25,000 | |
ELVN | Helen Louise Collins | CHIEF MEDICAL OFFICER | Mar 25, 2026 | Option Exercise | $2.48 | 40,000 | $99.2K | 65,000 | |
ELVN | Helen Louise Collins | CHIEF MEDICAL OFFICER | Mar 17, 2026 | Sale | $27.76 | 5,000 | $138.8K | 25,000 | |
ELVN | Helen Louise Collins | CHIEF MEDICAL OFFICER | Mar 17, 2026 | Option Exercise | $2.48 | 5,000 | $12.4K | 30,000 |